Managing Partner Flic Gabbay is delighted to annouce the appointment of Sharmila Kar to the medical affairs team. Sharmila has joined TranScrip following 7 years of leading in-country Medical Affairs teams in various companies. During her roles in Industry working for both large and small companies, she has had therapeutic experience and oversight of over 20 products from biologics to small molecules and products for rare diseases. Her experience focuses around pre-launch, post-marketing and supporting the full commercialisation of products throughout their life-cycle. She is particularly skilled at supporting market access teams to overcome barriers to reimbursement through KOL engagement, scientific communication and real world evidence generation. Sharmila will be joining the CNS, internal medicine and oncology therapeutic teams in TranScrip.
Sharmila’s experience has spanned 15 different therapy areas which align to different reimbursement models, from high cost biologics impacting local and regional healthcare budgets to highly specialised products reimbursed through national tenders and frameworks. She is adaptable, resourceful and commercially astute and through her 16 years’ experience of clinical work within the NHS, is able to develop compelling value arguments and narratives underpinned by real world evidence. Sharmila has worked extensively with marketing, market access and sales teams and as an ABPI final signatory, is experienced in the risk assessment of business projects, ensuring the highest standards of compliance against accepted Industry standards.
Sharmila has been involved in a wide range of medical affairs projects. These have included the development of Congress Symposia including topic and speaker selection and KOL engagement including advisory boards and focus groups with both clinicians and payers. She has extensive experience of training internal teams and managing medical teams including the development of appropriate KPIs. Sharmila has been involved in the scoping and initiation of post-authorisation safety studies and has a sound understanding of the use of UK data systems to enable evidence generation to support value arguments. She has worked with several UK clinical Registries including the BSRBR biologics registers and the National Haemophilia database and has experience of gathering outcomes data and quality of life data in several therapy areas.
Sharmila has worked closely with HTA teams in different companies to provide appropriate clinical oversight to health economic models, ensuring their clinical plausibility and helping to manage uncertainty with credible assumptions. She is also adept at developing the narrative and uncovering opportunities to generate evidence to help support arguments for the potential clinical effectiveness of a new product.
Through her eclectic mix of experience and ability to stay in tune with the evolving healthcare payer environment, Sharmila is a results-orientated problem-solver who can communicate effectively to a wide range of external stakeholders. She is media trained and engages effectively with policy makers, clinicians and patient group representatives alike.
• CNS and Pain
• Internal Medicine
• Medical Affairs and Commercial (including market access and outcomes research)
• Drug Safety, PV and Risk Management
• Commercial Strategy and Portfolio Management
Sharmila graduated from Charing Cross and Westminster medical school in 1993 with an intercalated BSc in clinical sciences. She spent 3 years training in ophthalmology in the NHS and gained the FRCOphth qualification in 1998. She then left hospital medicine to become a GP and maintained her interest in ophthalmology as a GP with a special interest. She obtained the MRCGP qualification in 2001. During her time as a GP and whilst a practising full-time Partner, she project-managed and led the successful relocation of her practice to a purpose built medical centre, a project spanning over 3 years which was completed in 2008. She has completed formal training for the Diploma in pharmaceutical medicine and is an affiliate member of the Faculty of Pharmaceutical Medicine and holds a current license to practice.